Physician profile
Julissa Baez
NPI 1609091909
$1,764.36
in general payments reported to CMS, 2019-2025
11 companies · $302 in 2025
The $302 reported for 2025 was more than what 89% of Hospice and Palliative Medicine (Pediatrics) providers received nationally (typical 2025 total: $50.56).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $131 · 2021: $185 · 2022: $191 · 2023: $218 · 2024: $250 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $682.04 | 2019-2025 | Nucala, Bexsero, Pediarix |
| Pfizer INC. | $400.26 | 2019-2025 | |
| Kaleo, INC. | $210.39 | 2022-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $171.12 | 2019-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Seqirus USA INC | $140.80 | 2021-2024 | Flucelvax Quadrivalent, Flucelvax |
| Sanofi Pasteur INC. | $57.31 | 2019-2021 | |
| Phadia US INC. | $31.68 | 2019-2020 | |
| Lnhc, INC | $21.62 | 2025 | Zelsuvmi |
| Alk-Abello, INC | $20.86 | 2025 | Neffy |
| Incyte Corporation | $14.33 | 2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $13.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julissa Baez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.